Africa News Line Monday, 12.05.2022, 11:18 AM
Welcome Guest | RSS
Site menu

Main » 2022 » August » 23

ST. GALLEN, Switzerland - Monday, 22. August 2022

 

U.S. District Court for the District of Delaware rules Teva Pharmaceuticals infringes VFMCRP patent

Disputes with all other Abbreviated New Drug Application (ANDA) filers regarding Velphoro® have been settled

 

(BUSINESS WIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 which covers the formulation for Velphoro® (sucroferric oxyhydroxide). The decision, subject to appeal, holds that the generic sucroferric oxyhydroxide product proposed by Teva Pharmaceuticals USA, Inc., in its Abbreviated New Drug Application (ANDA) will infringe the Velphoro® U.S. patent no. 9,561,251, which expires in July 2030 (including pediatric extension). Currently, Velphoro® is protected by multiple Orange Book listed patents which e ... Read more »

Views: 21 | Added by: africa-live | Date: 08.23.2022 | Comments (0)

ST. GALLEN, Switzerland & SAN DIEGO - Monday, 22. August 2022

 

A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023

If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical need in IgA nephropathy (IgAN) in Europe

Views: 29 | Added by: africa-live | Date: 08.23.2022 | Comments (0)

(BUSINESS WIRE) -- Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/


Permalink
https://www.aetoswire.com/en/news/2208202226639
Contacts
Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
Tel: +81 3 5843 8046 (TOKYO)
info@solasia.co.jp

Views: 26 | Added by: africa-live | Date: 08.23.2022 | Comments (0)

PHILADELPHIA--(BUSINESS WIRE)--Project Management Institute (PMI) today announced that its Board of Directors has named Pierre Le Manh as President and Chief Executive Officer (CEO).

Starting September 1, Pierre Le Manh, a veteran CEO of professional services and knowledge industries, will lead PMI’s fast-growing global organization and oversee the continued execution of PMI’s Impact Strategy. In his role, Pierre will also serve as the lead advocate for PMI’s global organization and close to a hundred million project professionals worldwide.

“We are very excited to bring Pierre Le Manh on board after a thorough selection process,” said Jennifer Tharp, PMP, Chair of PMI’s Board of Directors. “We have big ambitions for the future of our profession and the Project Management Institute as a leading global organization. Pierre brings the global experience and credentials to accelerate PMI’s current business and further our i ... Read more »

Views: 33 | Added by: africa-live | Date: 08.23.2022 | Comments (0)

Search

Entries archive

Calendar